ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY

肛门生殖器癌——流行病学、生物化学和免疫学

• 批准号: 6102322
• 负责人: JANET R DALING
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 1999-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102322
• 关键词: antiviral antibody; biochemistry; cancer risk; cervix neoplasms; herpes simplex virus 2; human papillomavirus; human subject; interview; neoplasm /cancer epidemiology; neoplasm /cancer immunology; oral contraceptives; rectum neoplasms; reproductive system neoplasm; serology /serodiagnosis; sex behavior; sexually transmitted diseases; statistics /biometry; tobacco abuse; vagina neoplasms; viral carcinogenesis; virus DNA; vulva neoplasms; western blottings

This is a proposal to continue our case-control studies investigating the role of human papillomaviruses (HPV) in the development of anogenital cancers. The study will be conducted primarily in three counties of Western Washington that are covered by the population-based Cancer Surveillance System (CSS), a tumor registry that participates in the Surveillance Epidemiology and End Results Program (SEER) of the National Cancer Institute. (Penile, adenocarcinoma in situ of the cervix, and vaginal cancers from ten additional counties will be included to provide a sufficient sample size.) All men and women aged 18-74 with one of six malignancies will be identified and invited to participate, and we estimate the following number of cases will be successfully interviewed: invasive cancer of the cervix (248 cases); anal and perianal cancer (108 cases); vulvar cancer (164 cases); penile cancer (48 cases); adenocarcinoma of the cervix (96 cases); and cancer of the vagina (60 cases). Eligible subjects will be all individuals with a diagnosis of one of these six cancers during a five-year period from July 1994 - June 1998. Cases and appropriate controls will be interviewed regarding a history of sexually-transmitted diseases, as well as other known risk factors for each specific site. Tissue specimens from surgery will be obtained from all cases and will be probed for evidence of human papillomavirus using molecular hybridization techniques. Blood samples will be collected for all cases and controls and analyzed for evidence of prior exposure to herpes simplex virus type 2 and for several types of HPV using currently available tests. Additional sera will be frozen for future determination of HPV antibodies as new and/or more sensitive serologic tests are developed for HPV.